Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
Cytokinetics (CYTK) opened its ninth annual Communications Grant Program for patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure, with an application deadline of October 2, 2026.
The program will award grants to support communications, marketing and outreach initiatives, potentially funding programming or personnel. Eligible applicants are nonprofit or registered charities in the United States, Canada, Europe or the United Kingdom that serve HCM or heart failure communities. Applications are evaluated by a Cytokinetics committee, with 2026 grant recipients to be announced in January 2027.
Cytokinetics (CYTK) will participate in several healthcare investor conferences in September 2026, each featuring a management fireside chat.
Events include the Citi 2026 BioPharma Back to School Conference on Sept. 9 at 3:00 PM ET, the Cantor Global Healthcare Conference 2026 on Sept. 10 at 11:30 AM ET, the Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 14 at 7:45 AM ET, and the Bernstein 3rd Annual Healthcare Forum on Sept. 23 at 8:50 AM ET, all in New York, NY. Live webcasts and 90-day replays will be available via the Investors & Media section of the Cytokinetics website.
Cytokinetics (Nasdaq: CYTK) reported additional Phase 3 data for cardiac myosin inhibitor aficamten (MYQORZO) from ACACIA-HCM and MAPLE-HCM, presented as Late Breaking Clinical Trials at ESC Congress 2026 and published in leading cardiology journals.
In non-obstructive HCM, a pre-specified exploratory analysis of ACACIA-HCM showed that aficamten improved measures of diastolic function, including peak E and septal e’ velocities, with septal E/e’ and left atrial volume index demonstrating statistically significant improvements with longer treatment exposure (up to 72 weeks). Left ventricular wall thickness decreased by 0.2 cm and ventricular volumes increased, while a modest reduction in ejection fraction remained within the normal range.
In obstructive HCM, a post-hoc MAPLE-HCM analysis found aficamten improved peak VO2 versus metoprolol regardless of prior beta-blocker use, with least squares mean differences of +3.1 and +1.9 mL/kg/min, respectively, and consistent benefits across key secondary endpoints and similar safety across pre-trial treatment groups.
Cytokinetics (Nasdaq: CYTK) reported that Phase 3 trial ACACIA-HCM of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy met both dual primary endpoints at Week 36, showing statistically significant improvements versus placebo in KCCQ Clinical Summary Score (LSM difference 3.0; p=0.021) and maximal exercise performance (pVO₂) (LSM difference 0.67 ml/kg/min; p=0.003).
Key secondary endpoints, including ≥1-class NYHA improvement, composite CPET z-score and NT-proBNP, also reached statistical significance, while left atrial volume index and time to first cardiovascular event did not. Serious adverse events, heart failure events and LVEF <50% occurred more frequently with aficamten. Based on these results, Cytokinetics plans to submit a supplemental NDA in 4Q 2026 for aficamten in adult symptomatic nHCM. Results were presented at ESC Congress 2026 and published in The New England Journal of Medicine.
Cytokinetics (Nasdaq: CYTK) announced multiple presentations at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, from August 28-31, 2026. Sessions will highlight aficamten data from the ACACIA-HCM and MAPLE-HCM studies in hypertrophic cardiomyopathy, plus additional poster presentations and an investor event.
Cytokinetics (Nasdaq: CYTK) reported that on August 14, 2026 it granted stock options for 27,565 shares and 18,273 RSUs to 12 new employees as material inducement awards under Nasdaq Listing Rule 5635(c)(4). The options have a $74.13 exercise price, 4-year vesting and 10-year term, while RSUs vest over 3 years.
Cytokinetics (Nasdaq: CYTK) reported Q2 2026 total revenues of $28.6 million, including $25.3 million in MYQORZO net product revenue ($23.0 million U.S., $2.3 million initial German inventory) and $3.3 million in collaboration revenue, with no license or milestone revenue versus $64.4 million a year earlier.
Q2 GAAP R&D expenses were $97.8 million and SG&A expenses were $104.4 million; net loss was $198.8 million or $(1.50) per share, compared to $(134.4) million or $(1.12) per share in Q2 2025. Cytokinetics ended June 30, 2026 with about $1.7 billion in cash, cash equivalents and investments, boosted by a public equity offering of 11.34 million shares at $71.00, generating net proceeds of approximately $760.1 million.
The company highlighted commercial launch progress for MYQORZO in obstructive HCM, including Germany launch and U.K. approval with NICE recommendation, and positive Phase 3 ACACIA-HCM results in non-obstructive HCM, meeting dual primary endpoints and key secondary endpoints, supporting a planned supplemental NDA filing in Q4 2026.
Cytokinetics (Nasdaq: CYTK) announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for MYQORZO (aficamten) to treat symptomatic (NYHA class II‑III) obstructive hypertrophic cardiomyopathy (oHCM) in eligible adult patients across the United Kingdom.
Simultaneously, the National Institute for Health and Care Excellence (NICE) issued positive guidance recommending aficamten as an option for eligible adults with symptomatic oHCM in England and Wales, as add‑on to optimised standard care or alone when those therapies are contraindicated, subject to a commercial arrangement. Authorisation relied on phase 3 SEQUOIA‑HCM data in 282 adults, where aficamten showed a statistically significant improvement in peak oxygen uptake versus placebo (least squares mean difference 1.7 mL/kg/min; p < 0.001). MYQORZO is under additional safety monitoring, and healthcare professionals are asked to report suspected adverse reactions via the MHRA Yellow Card Scheme.
Cytokinetics (Nasdaq: CYTK) will report its second quarter 2026 results on August 6, 2026, at 4:00 PM Eastern Time. The company’s senior management will then host an earnings conference call at 4:30 PM Eastern Time to review financial results and provide business updates.
The live webcast and a six-month archived replay will be accessible via the Investors & Media section of Cytokinetics’ website or through the dedicated Q2 2026 earnings conference call link.
Cytokinetics (Nasdaq: CYTK) granted inducement equity awards on July 15, 2026 under Nasdaq Listing Rule 5635(c)(4) to 10 new employees. The awards include stock options for 21,220 shares at an exercise price of $82.62 and 14,067 RSUs, with multi‑year vesting schedules.